Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Blood blood.2025029210.

https://doi.org/10.1182/blood.2025029210

Published: 2025

Includes: Supplemental data

Journal Articles

NF-κB is a potential therapeutic target for histone deacetylase inhibitor-resistant cutaneous T-cell lymphoma

Akihiro Kitadate, Yuto Takahashi, Sayaka Iwama, Wataru Kuroki, Ko Abe, Masahiro Yamada, Sho Ikeda, Naoto Takahashi

Blood (2025) 146 (Supplement 1): 6825.

https://doi.org/10.1182/blood-2025-6825

Published: 2025

Journal Articles

A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation

Vaidehi Krishnan, Xi Ren, Kian Leong Lee, Radhika Sonthalia, Prasanna Venkatesh, Mengge Yu, Pavithra Shyamsunder, John Ouyang, Xinyi Yang, Florian Schmidt, Verity Saunders, Naranie Shanmuganathan, Charles Chuah, Naoto Takahashi, Susan Branford, Timothy Hughes, Shyam Prabhakar, Sin Tiong Ong

Blood (2025) 146 (Supplement 1): 74.

https://doi.org/10.1182/blood-2025-74

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

Real-world survival outcomes of Japanese adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with ponatinib

Naoto Takahashi, Yoshiaki Yanai, Yoshiyuki Shibasaki, Tsuneko Mizuno, Norihiro Nakamichi

Blood (2025) 146 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2025-1541

Published: 2025

Journal Articles

The impact of NR1I2 gene polymorphism and body weight on asciminib pharmacokinetics in patients with chronic myeloid leukemia

Naoto Takahashi, Yumiko Akamine, Masatomo Miura

Blood (2025) 146 (Supplement 1): 5043.

https://doi.org/10.1182/blood-2025-5043

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.

Blood (2025) 146 (Supplement 1): 5546.

https://doi.org/10.1182/blood-2025-5546

Published: 2025

Journal Articles

Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI

Blood (2025) 146 (Supplement 1): 5545.

https://doi.org/10.1182/blood-2025-5545

Published: 2025

Journal Articles

Prognostic value of baseline FDG PET/CT total metabolic tumor volume and MYC/BCL2 double expression status in patients with diffuse large B-cell lymphoma

Shodai Takahashi, Akihiro Kitadate, Kazuma Nakajima, Naoto Takahashi

Blood (2025) 146 (Supplement 1): 3660.

https://doi.org/10.1182/blood-2025-3660

Published: 2025

Journal Articles

CTLA-4 + Effector Regulatory T Cells May Contribute to Maintenance of Treatment-Free Remission in Chronic Myeloid Leukemia

Yuki Fujioka, Naoto Takahashi, Takayo Nagao, Shigeharu Ueki

Blood (2024) 144 (Supplement 1): 6578.

https://doi.org/10.1182/blood-2024-208815

Published: 2024

Journal Articles

Identification of a Novel Function of B2M Involving T-Cell Exhaustion Via P-Selectin Ligand Upregulation in Diffuse Large B-Cell Lymphoma

Katsuyoshi Takata, Hidekazu IIoka, Shuta Tomida, Yuting Liu, Shujiro Okuda, Hiroyuki Usuda, Takashi Kawasaki, Akihiro Kitadate, Naoto Takahashi, Gerben Duns, Yasuharu Sato, Christian Steidl, Daisuke Ennishi

Blood (2024) 144 (Supplement 1): 331.

https://doi.org/10.1182/blood-2024-202199

Published: 2024

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

AML-Mrg Mutation Spectrum and Its Prognosis: A Japanese Multicenter Study HM01-02 Analysis with Full Analysis Sets

Blood (2024) 144 (Supplement 1): 6123.

https://doi.org/10.1182/blood-2024-202327

Published: 2024

Journal Articles

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, Jorge Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Susanne Saussele, Francois Mahon, Tim H. Brümmendorf, Shruti Kapoor, Tracey McCulloch, Peter Schuld, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 6388.

https://doi.org/10.1182/blood-2023-186773

Published: 2023

Journal Articles

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

Takeshi Kondo, Eri Matsuki, Tomoiku Takaku, Masaya Okada, Kazunori Murai, Chikashi Yoshida, Naoki Watanabe, Naoto Takahashi, Shinya Kimura, Itaru Matsumura

Blood (2023) 142 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2023-174169

Published: 2023

Journal Articles

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Naoko Hosono, Takahiro Yamauchi, Chi Sung-Gi, Hironori Arai, Kentaro Fukushima, Daisuke Ikeda, Satoshi Iyama, Akihiko Gotoh, Takayuki Ikezoe, Chikashi Yoshida, Goichi Yoshimoto, Junya Kanda, Naoto Takahashi, Emiko Sakaida, Kensuke Usuki, Yosuke Minami

Blood (2023) 142 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2023-184546

Published: 2023

Journal Articles

Tumor Suppressive Mir-7 Targeting PSME3 Improves the Efficacy of Histone Deacetylases Inhibitors in Multiple Myeloma

Masahiro Yamada, Sho Ikeda, Wataru Kuroki, Sayaka Iwama, Yuto Takahashi, Akihiro Kitadate, Fumito Abe, Hiroyuki Tagawa, Naoto Takahashi

Blood (2023) 142 (Supplement 1): 6592.

https://doi.org/10.1182/blood-2023-173475

Published: 2023

Journal Articles

The Real-World Outcomes of Ponatinib in 724 Patients with CML and Ph + ALL : A Post-Marketing Surveillance Study with a Special Interest in Arterial Occlusive Events in Japan

Naoto Takahashi, Takeshi Kondo, Yuji Ikari, Yoshihiro Fukumoto, Kiyohiko Hatake, Akira Masunari, Seiji Nishibayashi, Akiko Kageyama, Yasuhiko Fukuta, Arinobu Tojo

Blood (2023) 142 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2023-174324

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

NF-κB is a potential therapeutic target for histone deacetylase inhibitor-resistant cutaneous T-cell lymphoma

A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation

Real-world survival outcomes of Japanese adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with ponatinib

The impact of NR1I2 gene polymorphism and body weight on asciminib pharmacokinetics in patients with chronic myeloid leukemia

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.

Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI

Prognostic value of baseline FDG PET/CT total metabolic tumor volume and MYC/BCL2 double expression status in patients with diffuse large B-cell lymphoma

CTLA-4 + Effector Regulatory T Cells May Contribute to Maintenance of Treatment-Free Remission in Chronic Myeloid Leukemia

Identification of a Novel Function of B2M Involving T-Cell Exhaustion Via P-Selectin Ligand Upregulation in Diffuse Large B-Cell Lymphoma

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

AML-Mrg Mutation Spectrum and Its Prognosis: A Japanese Multicenter Study HM01-02 Analysis with Full Analysis Sets

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Tumor Suppressive Mir-7 Targeting PSME3 Improves the Efficacy of Histone Deacetylases Inhibitors in Multiple Myeloma

The Real-World Outcomes of Ponatinib in 724 Patients with CML and Ph + ALL : A Post-Marketing Surveillance Study with a Special Interest in Arterial Occlusive Events in Japan

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only